01:42 , Dec 13, 2018 |  BC Extra  |  Company News

Management tracks: Tamura reclaims CEO role at Sosei

Sosei Group Corp. (Tokyo:4565) said Peter Bains will step down as president and CEO and resign as director on Dec. 31. Executive Chairman, founder and former CEO Shinichi Tamura will replace Bains, effective Jan. 1....
00:36 , Nov 7, 2018 |  BC Extra  |  Company News

Management tracks: Five Prime, Alder

Five Prime Therapeutics Inc. (NASDAQ:FPRX) hired David Smith as EVP and CFO, effective Nov. 26. He will replace Linda Rubinstein, who was interim CFO of the cancer company. Smith was COO of IntegenX Inc. until...
18:02 , Oct 19, 2018 |  BC Week In Review  |  Company News

Express Scripts adds Aimovig, Emgality to new value-based migraine program; excludes Ajovy

Express Scripts Holding Co. (NASDAQ:ESRX) will include two of three FDA approved migraine prevention drugs in its value-based program for migraine, which it unveiled Oct. 17. The PBM gave the nod to Aimovig erenumab-aooe from...
23:16 , Oct 17, 2018 |  BC Extra  |  Company News

Express Scripts adds Aimovig, Emgality to new value-based migraine program; excludes Ajovy

Express Scripts Holding Co. (NASDAQ:ESRX) will include two of three FDA approved migraine prevention drugs in its value-based program for migraine, which it unveiled Wednesday. The PBM gave the nod to Aimovig erenumab-aooe from Amgen...
20:17 , Oct 5, 2018 |  BC Week In Review  |  Clinical News

FDA approves Lilly's mAb to prevent migraine

Eli Lilly and Co. (NYSE:LLY) said FDA approved Emgality galcanezumab-gnlm to prevent migraine in adults. The mAb against calcitonin-related gene peptide (CGRP) is the third in its class that FDA has approved. Lilly said Emgality...
03:46 , Sep 29, 2018 |  BioCentury  |  Product Development

Deferred differentiation in migraine

The best hope for CGRP antagonists to differentiate themselves lies in data that aren’t yet available. In the meantime, the makers of the migraine therapies will likely have to trade discounts on their already reasonable...
14:13 , Sep 28, 2018 |  BC Extra  |  Company News

FDA approves Lilly's mAb to prevent migraines

Eli Lilly and Co. (NYSE:LLY) said FDA approved Emgality galcanezumab-gnlm to prevent migraine in adults. The mAb against calcitonin-related gene peptide (CGRP) is the third in its class that FDA has approved. Lilly said Emgality...
17:36 , Sep 21, 2018 |  BC Week In Review  |  Clinical News

FDA approves Teva's Ajovy, second CGRP inhibitor to prevent migraine

FDA approved Ajovy fremanezumab-vfrm from Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA) on Sept. 14 to prevent migraine in adults. The mAb targeting the calcitonin gene-related peptide ligand is the second in its class approved...
00:20 , Sep 15, 2018 |  BC Extra  |  Company News

FDA approves Teva's Ajovy, second CGRP inhibitor to prevent migraine

FDA approved Ajovy fremanezumab-vfrm from Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA) to prevent migraine in adults. The mAb targeting the calcitonin gene-related peptide ligand is the second in its class approved in the indication....
21:55 , Jul 23, 2018 |  BC Extra  |  Company News

Management tracks: CStone, BMS

Immuno-oncology company CStone Pharmaceuticals Co. Ltd. (Suzhou, China) hired Richard Yeh as CFO. He was managing director and business unit leader of Asia Pacific healthcare equity research at Goldman Sachs. Reports of the move emerged...